AAV11 Vector Platform for Potent Single-Dose Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV-based vaccines require multiple doses and have limited potency against a wide range of infections and cancers, and they struggle to adapt quickly to emerging variants of concern.
Innovation Solution
Development of an optimized AAV11 vector platform that includes an AAV11 capsid protein with modified amino acid sequences and a nucleic acid encoding an immunogenic polypeptide, such as a coronavirus spike protein, linked to a promoter like mini-CMV, to enhance immune response and adaptability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If AAV-based vaccines are used, then vaccine stability and manufacturing scalability are improved, but dosing potency and immune response strength are insufficient
Solution Approach 1:
The patent modifies the AAV capsid protein amino acid sequence to create optimized variants with enhanced transduction efficiency and immune response. Specific amino acid substitutions in the capsid structure alter viral entry mechanisms and cellular uptake, thereby increasing dosing potency while preserving the stability advantages of the AAV platform.
2Ease of manufacture
If standard AAV vectors are used, then manufacturing simplicity is maintained, but adaptability to emerging variants is limited
Solution Approach 1:
The patent creates a dynamic vaccine platform where the immunogenic polypeptide can be rapidly exchanged to match emerging viral variants. The optimized AAV11 vector backbone remains constant for manufacturing consistency, while the transgene encoding the immunogenic polypeptide can be quickly updated to target new variants, enabling fast adaptation without compromising manufacturing simplicity.
3Loss of time
If single dose vaccination is implemented, then treatment time is reduced, but immune response durability is insufficient
Solution Approach 1:
The patent employs a composite approach combining optimized AAV11 capsid proteins with specific immunogenic polypeptides and regulatory elements (promoters, polyA sequences). This composite vector design enhances transduction efficiency and antigen expression, enabling durable immune responses from a single dose by maximizing the immunogenicity and persistence of the vaccine antigen.
Data Source
AI summary
The present application relates to compositions and methods for eliciting an immune response in a subject using an AAV11 vector comprising an AAV11 capsid protein and a nucleic acid encoding a transgene operably linked to a promoter, wherein the transgene encodes an immunogenic polypeptide.